Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | PTGES | O14684 | 3/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282269 | 0.93 | LMNA (0.68) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL302271 | 0.93 | LMNA (0.68) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL1711093 | 0.93 | LMNA (0.71) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL303907 | 0.93 | LMNA (0.65) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL302243 | 0.93 | LMNA (0.62) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL302427 | 0.92 | KMT2A (0.68) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL1710942 | 0.90 | LMNA (0.76) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL1711351 | 0.90 | LMNA (0.62) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL303534 | 0.90 | KMT2A (0.61) | LMNAKMT2AHPGDHTTSMN1; SMN2 | |
| SCHEMBL13065208 | 0.90 | LMNA (0.59) | LMNAKMT2AHPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | claimed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | claimed |
| JP-2012500834-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2344456-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | Xention Limited (GB) | 2011-07-20 | — | — | EP | claimed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| EP-2344456-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | Xention Limited (GB) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010130638-A1 | SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130638-A1 | SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | LMNA 1683/4885KMT2A 777/4885HPGD 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.